Two years post-merg­er, Flag­ship’s Sen­da re­fines pipeline and re­plen­ish­es the bank 

Sen­da Bio­sciences will look a lit­tle dif­fer­ent than it did two years ago when Flag­ship Pi­o­neer­ing un­wrapped the bow on the ven­ture, a merg­er of Sen­da and Kin­tai Ther­a­peu­tics.

Orig­i­nal­ly home to six pre­clin­i­cal pro­grams with am­bi­tions for treat­ing mul­ti­ple scle­ro­sis, Parkin­son’s, col­orec­tal can­cer, chron­ic kid­ney dis­ease, obe­si­ty and oth­er dis­eases, the start­up is fine-tun­ing its path and will soon present a clear­er scope of its fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER